Same molecule, different route
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: it mimics a natural gut hormone released after eating, acting on appetite-regulating areas of the brain to increase fullness, reduce hunger and dampen food cravings.[2] That mechanism is identical whether the semaglutide arrives as a weekly injection or a daily tablet, because it is the same active ingredient in both.[5]
The injection came first — a once-weekly subcutaneous injection introduced in 2021.[5] The pill is that same molecule reformulated as a once-daily oral tablet, which Novo Nordisk describes as the first oral GLP-1 receptor agonist licensed for weight management in adults.[1] So the honest headline is not a new drug but a new way to take an existing one, and the differences are all about route.
Pill and injection are the same semaglutide working the same way. The choice between them is a choice about route and routine — daily tablet with strict timing versus weekly injection with none — and it is made with a prescriber, weighing your history and preferences.
The two forms side by side
The pill and the injection use completely different dose numbers, so it helps to set out what each involves.
| Wegovy pill | Wegovy injection | |
|---|---|---|
| Route | Oral tablet, swallowed[1] | Subcutaneous injection, under the skin[5] |
| Frequency | Once daily[1] | Once weekly[5] |
| Maintenance dose | 25 mg once daily[1] | 2.4 mg once weekly[2] |
| Timing rules | Empty stomach, small amount of water, then a wait before eating[2] | No food or water timing rules |
| Licensed use | Weight management[1] | Weight management[7] |
The dose numbers are a trap: a 25 mg daily tablet and a 2.4 mg weekly injection are not a tenfold difference in "strength". They are different formulations absorbed in different ways — only a fraction of an oral dose crosses the stomach lining at all — so the milligrams on the box cannot be compared.
How the routine differs
For most people the real decision is less about the science than about which routine they can keep to — and here the two forms genuinely diverge.
The pill: convenient, but disciplined
The tablet's appeal is that there are no needles; the catch is timing. Getting a peptide like semaglutide to survive the stomach is hard, so the oral version is paired with an absorption enhancer that shields the drug long enough for a small amount to cross the stomach lining.[6] That window is narrow, so the instructions are strict: take it first thing on an empty stomach, with only a small amount of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medicines.[2] UK pharmacy guidance adds that it should be swallowed whole, never crushed, split or chewed.[10] One reported point in its favour: unlike some injectables, it is reported not to need refrigeration.[8] None of this is difficult, but it is daily, and must become a fixed habit for the medicine to absorb properly. Our dosage and how-to-take page covers the routine in full.
The injection: less frequent, no timing rules
The injection reverses the trade-off. There are no food or water rules and nothing to wait for — but it is an injection under the skin, which some people find a barrier in itself. Its rhythm is weekly rather than daily: fewer things to remember, though it means handling and, for some products, storing a device. Our sources do not set out the injection's dose ladder, so we do not reproduce one; what is documented is a maintenance dose of 2.4 mg once weekly.[2]
What the trials show — and what they can't tell you
This is the part most comparisons get wrong. The tablet's weight-management evidence comes from the OASIS programme; the study behind the approved 25 mg dose was OASIS 4, which ran for 64 weeks in adults with obesity, or overweight with weight-related complications, without type 2 diabetes, comparing oral semaglutide 25 mg against placebo alongside lifestyle support.[3] Novo Nordisk reports mean weight loss of about 16.6% among people who took the tablet as intended, against roughly 2.7% on placebo.[1] Across everyone regardless of how consistently they took it, mean weight loss was about 13.6% versus 2.4% on placebo.[4] Around 76% of people on the tablet lost at least 5% of their body weight, versus about 31% on placebo.[4]
Here is the honest limit: those figures come from the tablet's own trials. Our sources contain no head-to-head study that put one group on the pill and another on the injection — the injection's evidence was gathered separately, in different populations, over different lengths, counting drop-outs differently. Laying the pill's percentage next to an injection percentage from another study, as if the gap meant something, is a well-worn mistake rather than a real comparison. If you see a confident claim that one form gives "more" weight loss than the other, check whether it rests on a trial that actually compared them.
Side effects: broadly similar, per the manufacturer
Because it is the same molecule, the side-effect story is largely shared. Both forms are dominated by gastrointestinal effects — nausea, diarrhoea, vomiting, constipation, stomach pain — alongside headache and tiredness,[4] typically worst while the dose is being increased.[11] In OASIS 4, gastrointestinal adverse events affected about 74% of people on the tablet against 42% on placebo, and were mostly mild to moderate; the share who stopped because of side effects was similar between drug and placebo, at about 7% versus 6%.[3] Novo Nordisk describes the tablet's safety profile as comparable to the injectable and to previous semaglutide studies.[4] Our sources do not provide a symptom-by-symptom comparison in the same study, so — as with efficacy — we do not claim one form is gentler than the other.
Semaglutide carries a boxed warning in the US about a risk of thyroid C-cell tumours, based on animal studies, and it should not be used by people with certain thyroid or endocrine conditions.[4] Those cautions apply to the medicine, whichever form it takes, and they are decisions for a prescriber who knows your history. If you take any weight-loss medicine and experience side effects, you can report them through the MHRA Yellow Card scheme[9] and should speak to your GP or pharmacist. Our side effects page covers the warnings and cautions in full.
Switching between the two forms
Because both are semaglutide, moving between them is possible under a prescriber's direction. The Pharmaceutical Journal reports that someone already established on the 2.4 mg once-weekly injection can be transitioned directly to the 25 mg once-daily tablet.[2] That is a managed clinical change, not a swap to make on your own — the dose numbers are not comparable, and only a prescriber can set the plan.
Who might prefer which — a prescriber's call
It is tempting to want a rule of thumb, and that is exactly what to resist. The features above map onto preferences in obvious ways: someone who dislikes needles may be drawn to a tablet; someone who would struggle with a strict daily empty-stomach routine, or who prefers a weekly task they can otherwise forget, may find the injection easier to keep to. But those are starting points for a conversation, not a self-diagnosis. The choice also turns on things a page cannot see: your other medicines, your medical history, how you have tolerated GLP-1 medicines before, and clinical suitability for either form. That is why both forms are something a prescriber may discuss with you, never something you decide to take. The frequently asked questions and the development story behind the tablet can help you go into that conversation better informed.
How you would access either in the UK
Both forms are prescription-only medicines, so there is no lawful way to buy either without a consultation. A qualified prescriber assesses whether treatment is appropriate and which form fits, and a GPhC-registered pharmacy dispenses it against that prescription. At approval the tablet was, according to UK pharmacy guidance, available in the UK only privately;[11] it was not on the NHS, with access depending on a NICE technology appraisal still to be completed.[2] That mirrors how the injectable form reached the NHS — appraised, then offered only to defined groups of patients.[7] A site offering to sell semaglutide in any form with no prescription and no assessment is not operating lawfully, and what it supplies may not be a genuine, regulated medicine.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
Our sources contain no head-to-head trial comparing the two, so a clean side-by-side answer does not exist. What is published is OASIS 4, where Novo Nordisk reports mean weight loss of about 16.6% on oral semaglutide 25 mg taken as intended,[1] and about 13.6% regardless of adherence,[4] versus roughly 2–3% on placebo over 64 weeks. Those figures come from a separate trial in a separate group of people from the injection's studies, so they cannot simply be lined up against each other.
Can I switch from the Wegovy injection to the pill?
The Pharmaceutical Journal reports that someone established on the 2.4 mg once-weekly injection can be transitioned directly to the 25 mg once-daily tablet.[2] That is a plan for a prescriber to make and manage, not something to do on your own — the two forms use different dose numbers.
Why does the pill have to be taken on an empty stomach when the injection doesn't?
Semaglutide is a peptide, normally broken down in the stomach before it can be absorbed. The tablet's absorption enhancer protects a small amount long enough to cross the stomach lining, but that window is narrow — so it must be taken on an empty stomach with a little water and a wait before eating.[6][2] An injection bypasses the stomach entirely, so it has no food or water timing rules.
Which has fewer side effects, the pill or the injection?
Both are the same molecule and both are dominated by gastrointestinal effects. Novo Nordisk describes the tablet's safety profile as comparable to the injectable and to previous semaglutide studies.[4] Our sources contain no reliable symptom-by-symptom comparison, so we cannot say one form has fewer side effects. Report any side effect through the MHRA Yellow Card scheme.[9]
Is the pill or the injection better?
There is no single "better" form. They contain the same active ingredient and differ in route and routine: a tablet once a day with strict timing, or an injection once a week with none. Which trade-off suits someone depends on preferences, medical history and other medicines — which is why the choice belongs to a qualified prescriber.
References
- Novo Nordisk. Wegovy pill (oral semaglutide 25 mg) FDA approval announcement — first oral GLP-1 for weight management, once-daily 25 mg dosing, and the OASIS 4 adherent-estimand result (about 16.6% vs 2.7% placebo). novonordisk.com
- The Pharmaceutical Journal. "MHRA approves semaglutide oral tablets for weight loss" — UK licence (June 2026), mechanism of action, administration timing, the 2.4 mg once-weekly injection dose, injection-to-tablet switching, and NHS/NICE status (secondary source).
- American College of Cardiology. OASIS 4 trial summary (oral semaglutide 25 mg; NEJM, 17 September 2025) — design, gastrointestinal adverse events and discontinuation (secondary source).
- PR Newswire. "FDA approves Novo Nordisk's Wegovy pill" — the OASIS 4 treatment-policy result (13.6% vs 2.4% placebo), the ≥5% proportion, common side effects, comparable-to-injectable safety, and the boxed warning and contraindications (secondary source).
- GoodRx. Rybelsus vs Wegovy — same molecule; the injection is once-weekly subcutaneous semaglutide (introduced 2021) and the pill is once-daily oral (secondary source).
- Biopharma PEG. "What is SNAC in oral semaglutide?" — why the oral tablet needs an absorption enhancer and strict timing (secondary source).
- National Institute for Health and Care Excellence. TA875: semaglutide for managing overweight and obesity (injectable form; context for the pill's likely NHS route). nice.org.uk
- ABC News. FDA approves Wegovy pill — reported that the tablet does not require refrigeration (secondary source; single source, treat as reported).
- MHRA. Yellow Card scheme — report a suspected side effect. yellowcard.mhra.gov.uk
- Rightangled. Wegovy pill UK / oral semaglutide 2026 — guidance that the tablet should be swallowed whole, not crushed, split or chewed (secondary source; single source, treat as reported).
- Bolt Pharmacy. Wegovy pill UK guide — that at launch the tablet was available only on private prescription, and that side effects are typically worst during dose escalation (secondary source; single source, treat as reported).